Accelerating clinical trials and driving results for patients
Formed in 2019, The Amyloidosis Forum has been developed through a public-private partnership between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA). The overarching goal of the Forum is to optimize innovation and accelerate the advancement of new therapeutics by addressing scientific gaps and needs through the conduct of mutually beneficial scientific activities in the precompetitive domain that aid in the scientific evaluation of the efficacy and safety of new therapies.
How We Work
The Amyloidosis Forum has established a collaborative framework with appropriate stakeholders, including government, academic, scientific, patient, and industry organizations, to foster scientific collaborations. The Forum convenes regular meetings and has defined both workstreams and working groups to focus on key areas. The Forum is committed to publishing the outcomes from these initiatives.
Thank You to Our Supporters
